CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Hematologic Oncology Update
00:00
Bispecifics versus CAR T in DLBCL
Loretta and Jeremy discuss bispecifics' off‑the‑shelf advantage and starting CAR T evaluation early.
Play episode from 17:11
Transcript
